/HRMY
HRMY Stock - Harmony Biosciences Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$37.81+0.91%
+$0.34 (+0.91%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.84
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.88
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+28.0%upside
Target: $48.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HRMY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$37.43 – $38.19
TARGET (TP)$48.40
STOP LOSS$34.79
RISK/REWARD1:3.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.80
52W High$40.93
52W Low$25.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $714.73M | $582.02M | $437.86M | $305.44M | $159.74M |
| Gross Profit | $557.92M | $460.79M | $354.37M | $249.92M | $132.00M |
| Gross Margin | 78.1% | 79.2% | 80.9% | 81.8% | 82.6% |
| Operating Income | $190.83M | $192.03M | $120.19M | $87.53M | $16.99M |
| Net Income | $145.49M | $128.85M | $181.47M | $34.60M | $-36,944,000 |
| Net Margin | 20.4% | 22.1% | 41.4% | 11.3% | -23.1% |
| EPS | $2.56 | $2.17 | $3.07 | $0.60 | $-1.12 |
Company Overview
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
65%
Hold / Neutral
4
24%
Sell / Underperform
2
12%
Analyst Consensus🟡 Mixed
11 Bullish6 Neutral/Bearish
Price Targets
$52
Average Target
↑ 38.8% Upside
Now
$30
Low
$52
Average
$75
High
Based on 17 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 21st 2025 | Truist | Initiation | Buy | $48 |
| July 10th 2025 | Goldman | Resumed | Neutral | $33 |
| June 2nd 2025 | Oppenheimer | Resumed | Outperform | $61 |
| February 11th 2025 | Deutsche Bank | Initiation | Buy | $55 |
| December 17th 2024 | H.C. Wainwright | Initiation | Buy | $75 |
| October 10th 2024 | Raymond James | Resumed | Outperform | - |
| September 10th 2024 | UBS | Initiation | Buy | $56 |
| June 21st 2024 | Citigroup | Initiation | Buy | $48 |
| January 2nd 2024 | BofA Securities | Downgrade | Underperform | $30 |
| September 25th 2023 | Goldman | Downgrade | Sell | $31← $40 |
| September 7th 2023 | Berenberg | Initiation | Buy | $59 |
| April 20th 2023 | BofA Securities | Initiation | Neutral | $35 |
| October 14th 2022 | Janney | Upgrade | Buy | $61← $57 |
| October 14th 2022 | Jefferies | Upgrade | Buy | $61← $57 |
| August 3rd 2022 | Jefferies | Downgrade | Hold | $57 |
Earnings History & Surprises
HRMYBeat Rate
78%
Last 18 quarters
Avg Surprise
+105.6%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$0.87
Q4 2025
EPS Surprise History
Q1 24
-6.2%
$0.45vs$0.48
Q2 24
+11.7%
$0.67vs$0.60
Q3 24
+433.3%
$0.20vs$-0.06
Q4 24
+17.9%
$0.79vs$0.67
Q1 25
+14.9%
$0.85vs$0.74
Q2 25
+32.2%
$0.78vs$0.59
Q3 25
-12.8%
$0.68vs$0.78
Q4 25
-5.4%
$0.87vs$0.92
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $0.79 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.92 | $0.87 | -5.4% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $0.78 | $0.68 | -12.8% | ✗ MISS |
Q2 2025 | May 6, 2025 | $0.59 | $0.78 | +32.2% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $0.74 | $0.85 | +14.9% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $0.67 | $0.79 | +17.9% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.06 | $0.20 | +433.3% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $0.60 | $0.67 | +11.7% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $0.48 | $0.45 | -6.2% | ✗ MISS |
Q4 2023 | Oct 31, 2023 | $0.65 | $0.75 | +15.4% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $0.63 | $0.56 | -11.1% | ✗ MISS |
Q2 2023 | May 2, 2023 | $0.44 | $0.48 | +9.1% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $0.58 | $0.79 | +36.2% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $0.10 | $0.95 | +850.0% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $0.40 | $0.57 | +42.5% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $0.25 | $0.51 | +104.0% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $0.32 | $0.63 | +96.9% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $0.27 | $0.51 | +88.9% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $0.19 | $0.54 | +184.2% | ✓ BEAT |
Latest News
Beacon Biosignals Collaborates With Harmony Biosciences To Incorporate Quantitative EEG Measurements Into Two Of Harmony's Phase 3 Studies Of HBS-301 For Narcolepsy And Idiopathic Hypersomnia
📈 PositiveBenzinga•Dec 16, 2025, 11:31 AM
Harmony Biosciences' EPX-100 Shows ~50% Seizure Reduction And Favorable Safety In Dravet Syndrome Phase 3 Extension Data Presented At AES 2025
📈 PositiveBenzinga•Dec 8, 2025, 01:07 PM
Harmony Biosciences To Highlight New Open-Label Extension Data From Its Investigation Of EPX-100 In Ongoing Phase 3 ARGUS Trial For Treatment Of Dravet Syndrome At 2025 AES Annual Meeting
📈 PositiveBenzinga•Dec 2, 2025, 01:27 PM
Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $46
📈 PositiveBenzinga•Dec 1, 2025, 01:51 PM
HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target
📈 PositiveBenzinga•Nov 24, 2025, 05:21 PM
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $42 Price Target
📈 PositiveBenzinga•Nov 24, 2025, 03:03 PM
Harmony Biosciences Announces Results From Bioequivalence And dosing Optimizing Studies For Pitolisant, NDA To Be Submitted In Early 2026
📈 PositiveBenzinga•Nov 24, 2025, 01:09 PM
Harmony Biosciences Doses First Patient In Phase 1 Trial Of BP1.15205 For Central Disorders Of Hypersomnolence
📈 PositiveBenzinga•Nov 19, 2025, 01:08 PM
Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $39
📈 PositiveBenzinga•Nov 6, 2025, 04:59 PM
Harmony Biosciences Hldgs Affirms FY2025 Sales Guidance of $845.000M-$865.000M vs $845.646M Est
📈 PositiveBenzinga•Nov 4, 2025, 12:35 PM
Harmony Biosciences Q3 Adj. EPS $1.08 Beats $0.79 Estimate, Sales $239.455M Beat $223.680M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 12:34 PM
Harmony Biosciences shares are trading higher after the company reported record Q3 2025 WAKIX revenue of $239M and raised full-year guidance to $845M-$865M.
📈 PositiveBenzinga•Oct 23, 2025, 12:26 PM
Harmony Biosciences Reports Record Q3 2025 WAKIX Revenue Of $239M, Raises Full-Year Guidance From $820M-$860M To $845M-$865M
📈 PositiveBenzinga•Oct 23, 2025, 12:17 PM
UBS Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $43
➖ NeutralBenzinga•Oct 15, 2025, 03:28 PM
Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Lowers Price Target to $35
📈 PositiveBenzinga•Sep 25, 2025, 04:27 PM
Deutsche Bank Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $36
➖ NeutralBenzinga•Sep 25, 2025, 01:27 PM•Also:
HC Wainwright & Co. Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $55
➖ NeutralBenzinga•Sep 25, 2025, 12:25 PM
Harmony Biosciences Holdings shares are trading lower after the company announced its Phase 3 registrational clinical trial of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate. Also, Needham lowered its price target on the stock from $48 to $41.
📉 NegativeBenzinga•Sep 24, 2025, 03:02 PM
Needham Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $41
➖ NeutralBenzinga•Sep 24, 2025, 02:29 PM
Harmony Biosciences' Phase 3 RECONNECT Trial Of ZYN002 In Fragile X Syndrome Misses Primary Endpoint Amid Elevated Placebo Response Rate
📉 NegativeBenzinga•Sep 24, 2025, 12:30 PM
Frequently Asked Questions about HRMY
What is HRMY's current stock price?
Harmony Biosciences Holdings, Inc. (HRMY) is currently trading at $37.81 per share. The stock has moved +0.91% today.
What is the analyst price target for HRMY?
The average analyst price target for HRMY is $48.40, based on 1 analyst.
What sector is Harmony Biosciences Holdings, Inc. in?
Harmony Biosciences Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is HRMY's market cap?
Harmony Biosciences Holdings, Inc. has a market capitalization of $2.17 billion, making it a mid-cap company.
Does HRMY pay dividends?
No, Harmony Biosciences Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
AUPH
Aurinia Pharmaceuticals Inc.
$16.18
Mkt Cap: $2.1B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
IMCR
Immunocore Holdings plc
$36.01
Mkt Cap: $1.8B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
MNKD
MannKind Corporation
$5.84
Mkt Cap: $1.8B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
SION
Sionna Therapeutics, Inc.
$42.37
Mkt Cap: $1.9B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
Explore stocks similar to HRMY for comparison